欢迎来到360期刊网!
学术期刊
  • 学术期刊
  • 文献
  • 百科
电话

您当前的位置:    首页  >  SCI投稿 > JOURNAL OF MOLECULAR MEDICINE-JMM是不是SCI

Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells.

切换为中文

Abstract:

:Tumor invasion and metastasis involve processes in which actin cytoskeleton rearrangement induced by Fascin1 plays a crucial role. Indeed, Fascin1 has been found overexpressed in tumors with worse prognosis. Migrastatin and its analogues target Fascin1 and inhibit its activity. However, there is need for novel and smaller Fascin1 inhibitors. The aim of this study was to assess the effect of compound G2 in colorectal cancer cell lines and compare it to migrastatin in in vitro and in vivo assays. Molecular modeling, actin-bundling, cell viability, inmunofluorescence, migration, and invasion assays were carried out in order to test anti-migratory and anti-invasive properties of compound G2. In addition, the in vivo effect of compound G2 was evaluated in a zebrafish model of invasion. HCT-116 cells exhibited the highest Fascin1 expression from eight tested colorectal cancer cell lines. Compound G2 showed important inhibitory effects on actin bundling, filopodia formation, migration, and invasion in different cell lines. Moreover, compound G2 treatment resulted in significant reduction of invasion of DLD-1 overexpressing Fascin1 and HCT-116 in zebrafish larvae xenografts; this effect being less evident in Fascin1 known-down HCT-116 cells. This study proves, for the first time, the in vitro and in vivo anti-tumoral activity of compound G2 on colorectal cancer cells and guides to design improved compound G2-based Fascin1 inhibitors. KEY MESSAGES: • Fascin is crucial for tumor invasion and metastasis and is overexpressed in bad prognostic tumors. • Several adverse tumors overexpress Fascin1 and lack targeted therapy. • Anti-fascin G2 is for the first time evaluated in colorectal carcinoma and compared with migrastatin. • Filopodia formation, migration activity, and invasion in vitro and in vivo assays were performed. • G2 blocks actin structures, migration, and invasion of colorectal cancer cells as fascin-dependent.

展开更多

JOURNAL OF MOLECULAR MEDICINE-JMM

J MOL MED
最新影响因子:4.427 期刊ISSN:0946-2716 CiteScore:
出版周期:Monthly 是否OA:YES 出版年份:1995

期刊官方网址:http://link.springer.com/journal/109

期刊投稿地址:https://www.editorialmanager.com/jmme/default.aspx

自引率:2.00% 研究方向:医学-医学:研究与实验
出版地区:GERMANY

SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)

NCBI查询:PubMed Central (PMC)链接全文检索(pubmed central)

专业编辑在线一对一答疑及时解决您的问题

JOURNAL OF MOLECULAR MEDICINE-JMM 期刊简介

英文简介:

Official Organ of the "German Working Group for Gene Therapy (DAG-GT)" Official Organ of the "Biomedical Research Association (KBF)" The employment of molecular biology and gene technology has enhanced the understanding of human diseases creating a new branch of research - that of "molecular medicine". The Journal of Molecular Medicine (JMM) publishes original papers rapid communications review articles and correspondence of the highest quality pertinent to all aspects of human biology and pathophysiology. The application of research involving gene technology gene therapy molecular structural analysis genetic epidemiology and molecular and clinical pharmacology has made unprecedented progress and precision possible in the understanding prevention diagnosis and treatment of human diseases. These areas of molecular medicine therefore will be given particular attention by the editorial board. Papers describing in vitro or animal studies will be accepted if they are relevant to normal or pathological human biology. Please include at the end of the acknowledgements a declaration that the experiments comply with the current laws of the country in which the experiments were performed.

中文简介:(来自Google、百度翻译)

“德国基因治疗工作组”官方机构“生物医学研究协会”官方机构分子生物学和基因技术的应用提高了对人类疾病的认识,创造了一个新的研究分支——“分子医学”。分子医学杂志(JMM)出版与人类生物学和病理生理学有关的所有方面的最高质量的原始论文、快速通讯评论文章和通信。基因技术、基因治疗、分子结构分析、遗传流行病学、分子与临床药理学等方面的研究应用,在认识人类疾病的预防、诊断与治疗方面,取得了前所未有的进展和精度。因此,分子医学的这些领域将受到编辑委员会的特别关注。描述体外或动物研究的论文,如果与正常或病理的人类生物学有关,将被接受。请在确认信的末尾附上一份声明,声明实验符合实验所在国的现行法律。

申请加急绿色通道,投稿周期比同行快2-3个月 现在咨询

JOURNAL OF MOLECULAR MEDICINE-JMM 期刊中科院评价数据

最新中科院分区

大类(学科) 小类(学科) 学科排名
医学 GENETICS & HEREDITY(遗传学和遗传性) 2区
MEDICINE, RESEARCH & EXPERIMENTAL(医学,研究和试验) 2区
29/171
20/133

最新公布的期刊年发文量

年度总发文量 年度论文发表量 年度综述发表量
117 80 37
总被引频次:7195
特征因子:0.010880

影响因子趋势图

无法辨别期刊质量?专业编辑老师一对一讲解,现在咨询现在咨询

JOURNAL OF MOLECULAR MEDICINE-JMM 期刊CiteScore评价数据

最新CiteScore值

=

引文计数(2018)

文献(2015-2017)

=

次引用

篇文献

文献总数(2014-2016):
被引比率:%
SJR:
SCLmago期刊等级衡量经过加权后的期刊受引用次数,引用次数的加权值由施引期刊的学科领域和声望(SJR)决定。
SNIP:
每篇文章中来源出版物的标准化影响将实际受引用情况对照期刊所属学科领域中预期的受引用情况进行衡量。

CiteScore排名

序号 类别 排名 百分位

CiteScore趋势图

Scopus涵盖范围

无法辨别期刊质量?专业编辑老师一对一讲解,现在咨询现在咨询

JOURNAL OF MOLECULAR MEDICINE-JMM 期刊常见问题

热门常见问题

无法辨别期刊质量?专业编辑老师一对一讲解,现在咨询现在咨询

权益保障

  • 刊物信息可查
    刊物信息可查

    推荐刊物均可到国家新闻出
    版总署网站查询正刊

  • 严格保密协协议
    严格保密协协议

    可签署保密协议 ,不透露任
    何用户信息可跟踪进程,全程
    协议

  • 售后服务保障
    售后服务保障

    1对1服务,7x24小时在线

  • 企业信誉保障
    企业信誉保障

    11年经验沉淀,实体公司
    运营

品牌运营 , 成功助力数万用户

JOURNAL OF MOLECULAR MEDICINE-JMM 投稿经验

(由下方点评分析获得,5人参与,1058人阅读)

最新评论(不代表本站观点)

  • avatar

    liting7111

    杂志要求初审两周回复,一般一个月就能收到审稿意见了。纸质版不收版面费,OA的话收费,这是可选的。文章一般要求与临床相关,有机制研究就行。
    2020-05-10
  • avatar

    liting7111

    研究方向:基因治疗 信号通路

    审稿时间: 2个月内 接受率: 比较困难(25%命中)

    杂志文章质量很高,比较侧重基础结合临床。
    2020-03-06
  • avatar

    liting7111

    研究方向:自身免疫 分子机制 细胞凋亡

    接受率: 中等(50%命中)

    投稿后一审一个月不到,两个审稿人,一个没提什么意见,另外一个提了十几条,编辑给了大修,限期三个月。光补实验我就花了三个月时间,一一回复问题,投回两周接收。编辑和审稿人都比较nice,圣奥速度也快,觉得自己文章不错的可以投稿。
    2020-02-18
  • avatar

    liting7111

    研究方向:纤维化

    初审三周,给了很多意见,看的都头疼,不知道修改后能不能接受,只能加油改了。
    2019-09-20
  • avatar

    liting7111

    研究方向:肿瘤 靶向治疗 分子机制

    审稿时间: 2个月内

    编辑很nice,审稿人也很专业,编辑部效率特别高。
    2019-03-24

相关期刊

360期刊网

专注医学期刊服务11年

客服正在输入...

  • 我是360期刊网在线指导老师,请问您想咨询什么等级的期刊(省级、国家级、核心、SCI)?我们提供以下服务:

  • 1.学术期刊服务
    2.SCI期刊服务
    3.论文指导服务

  • 现在咨询抢0元论文评估名额

加微信获取期刊信息
x
立即咨询